研究課題/領域番号 |
22K18203
|
研究機関 | 東北大学 |
研究代表者 |
|
研究期間 (年度) |
2022-04-01 – 2025-03-31
|
キーワード | lymph node metastasis / checkpoint inhibitor / chemoimmunotherapy |
研究実績の概要 |
Immunotherapy using immune checkpoint inhibitors (ICIs) is revolutionizing cancer metastasis treatment. However, few head and neck cancer (HNC) patients respond to ICIs with a high incidence of immune-related Adverse Events (irAEs). Still, a majority of them fail to respond. We created experimental mouse model by injecting luciferase expressing tumor cells and ICIs were injected as mono- or sequentially with combination of docetaxel. Treatment effects were evaluated over time, and final confirmation was made histologically along with irAEs. We found more significant tumor inhibition in the chemo-immunotherapy groups than in mono-immunotherapy.
|
現在までの達成度 (区分) |
現在までの達成度 (区分)
2: おおむね順調に進展している
理由
At this moment, we have completed ICI effects on metastatic LN mouse model as a monotherapy or chemoimmunotherapy. We observed inhibition of tumor progression in the lymphatic drug delivery system delivered mono-ICI with he reduced irAEs. The chemoimmunotherapy group investigation is still on going as planned
|
今後の研究の推進方策 |
We plan to finish effect of chemoimmunotherapy for metastatic LN mouse model. Therefore, planning to broaden the effect of ICIs or chemoimmunotherapy for LN resected mouse model.
|
次年度使用額が生じた理由 |
The unused amount generated by the efficient promotion of research in the current fiscal year will be used in the next fiscal year (FY). This amount, together with the amount requested for FY2024, will be used to carry out research in FY2024.
|